New challenges in perioperative management of pancreatic cancer

Table 2 Major phase III trials of adjuvant therapy for resected Pancreatic ductal adenocarcinoma

Ref.	Year	n	Treatment arms	OS (mo)	P value	5-yr OS (%)
GITSG[15]	1985	21	CRT1/5-FU then 5-FU maintenance for 2 yr	20.0	0.035	19
		22	Observation	10.9		5
EORTC[16]	1999	60	2CRT/5-FU	17.1	0.09	20
		54	Observation	12.6		10
ESPAC-1[18]	2004	145	1CRT/5-FU +/- 5-FU/FA bolus for 6 cycles	15.9	0.05	10
		144	No CRT	17.9		20
CONKO-001[14]	2007	179	Gem 6 cycles	22.8	0.005	20.7
		175	Observation	20.2		10.4
RTOG 97-04[22] (pancreatic head only)	2008	187	Gem 3 wk, CRT/5-FU, Gem 3 mo	20.5	0.09	22
		194	5-FU 3 wk, CRT/5-FU, 5-FU 3 mo	17.1		18
ESPAC-3[21]	2010	551	5-FU/FA for 6 cycles	23.0	0.53	NA
		537	Gem for 6 cycles	23.6		NA

¹CRT:20 Gy + 5-FU bolus days 1-3 x 2;

²20 Gy + 5-FU continous infusion x 2. CRT: Chemoradiotherapy; 5-FU: 5-Fluorouracil; FA: Folinic acid; Gem: Gemcitabine; OS: Overall survival; NA: Not available.